KrasG12D siRNA-loaded mesenchymal stromal cells-derived exosomes (Codiak BioSciences)

N/A

Report date: 2025/02/28 10:23:17

Base Information

Drug NameKrasG12D siRNA-loaded mesenchymal stromal cells-derived exosomes (Codiak BioSciences)

Drug Alias NameKrasG12D siRNA-loaded mesenchymal stromal cells-derived exosomes (NCI/MD Anderson Cancer Center)iExosomes (NCI/MD Anderson Cancer Center)mesenchymal stromal cells-derived exosomes (National Cancer Institute/MD Anderson Cancer Center)MSCs-derived exosomes with KrasG12D siRNA (NCI/MD Anderson Cancer Center)MSCs-derived exosomes (NCI/MD Anderson Cancer Center)

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNABiologics > Exosomes > Stem cell-derived exosomes

Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog inhibitors

TargetsGTPase KRas

Therapy Area/IndicationsPancreatic NeoplasmsCarcinoma, Pancreatic Ductal

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesThe University Of Texas MD Anderson Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesCodiak BioSciences Inc

Inactive CompaniesN/A

Active IndicationsPancreatic NeoplasmsCarcinoma, Pancreatic Ductal

Inactive IndicationsN/A

Other Information

ATC CodeN/A